Introduction: Traditional informed consent approaches, involving separate discussions and
towards a learning health system (LHS), involving a bidirectional feedback loop whereby data collection is embedded into care delivery processes, and this evidence is used to improve care. 2 These features of CER/PCOR studies have prompted questions regarding the appropriateness of traditional informed consent mecha-
nisms. Requirements for informed consent for research in the United
States have a deep and important history, with regulations requiring consent for most studies having been promulgated after a series of unconscionable examples of research conducted without consent were brought to the attention of the American public. 3 However, some scholars have suggested that traditional consent procedures may not be ethically required in certain CER/PCOR contexts, such as when the treatments being compared are non-investigational and low risk, and differ from one another in ways that are not generally relevant to patients. 4, 5 Others have noted that traditional consent procedures are both complex and time-consuming, and may unnecessarily hinder research, thereby compromising the generation of important new knowledge, especially as CER moves from conventional research contexts to busy clinical practices. 6 Such critiques have led to various proposals for streamlined options for disclosure to patients and authorization. 3, [7] [8] [9] However, little consensus yet exists regarding the conditions under which such alternatives would be ethically permissible. [10] [11] [12] Recent empirical studies suggest patients may be open to alternate approaches to disclosure and consent in some CER/PCOR contexts. [13] [14] [15] [16] [17] A more limited number of studies have explored the views of Institutional Review Board (IRB) professionals 16, 18 and physicians 19 regarding informed consent for CER/PCOR; however, the perspective of the broader range of stakeholders involved in CER/PCOR remains underexplored.
Building on earlier work, 12, 17 we sought the views of a multistakeholder group on alternate approaches to disclosure and consent for 2 different types of CER/PCOR studies. We convened a deliberative engagement session (DES) to examine diverse stakeholders' perspectives about the acceptability and potential challenges associated with alternate models of informed consent, disclosure, and authorization for CER/PCOR studies, and whether those perspectives changed in the context of a LHS.
| METHODS

The Center for Medical Technology Policy and the Johns
Hopkins Berman Institute of Bioethics hosted a full-day, in-person, DES 12, 20 in April 2014 in Baltimore, MD with a broad sample of health care stakeholders. This multi-stakeholder DES was part of a larger study that used the same methods to capture patients' views on this topic.
12,21
| Stakeholder identification and recruitment
The research team identified 7 broad stakeholder categories relevant to the question of informed consent for CER/PCOR: (1) 
| Deliberative engagement session method
The DES agenda followed the approach described by Kass et al. 12 We held a 1-day, structured session in which short plenary presentations alternated with small group stakeholder discussions. Plenary presentations provided information on (1) CER, (2) the LHS (Exhibit 1), might have preferences, even in the absence of evidence about which is more effective. 5 After each plenary, stakeholders discussed the information at assigned, round tables of 6 to 8 diverse stakeholders, along with a facilitator and notetaker. Early discussions aimed to ensure that all stakeholders understood the key topics. Later sessions aimed to explore stakeholders' views regarding which disclosure and consent models they found acceptable and which they preferred for observational and randomized study designs for each of the 2 studies presented.
| Quantitative data collection and analysis
Upon arrival at the DES, participants completed a pre-test survey on an iPad. The survey collected demographic characteristics, professional characteristics (eg, stakeholder type), and attitudes towards the 3 disclosure/consent models as applied to 2 hypothetical CER hypertension studies (1 randomized, 1 observational). The 3 disclosure/consent models included (1) a "General Approval" approach where patients are informed that their health system routinely conducts certain types of low-risk CER, but patients are not notified regarding individual studies nor are they given an opportunity to opt out of participating, (2) an "Opt-Out" approach where clinicians provide a brief description of the study and patients are told they will be included unless they say they do not want to participate, and (3) a traditional informed consent or "Opt-In" approach where patients are given extensive oral and written information about the study and can only participate if they give their written permission.
At the end of the day, participants completed a post-DES survey assessing attitudes towards the 3 models, using the same iPad to enable analysis of paired responses. Survey data were analyzed using SAS version 9.3 and STATA version 12. Attitudinal responses were collapsed into dichotomous categories: "liked" ("somewhat" or "very much" liked) and "didn't like" ("neutral", "somewhat disliked", or "really disliked"). McNemar's test was used to compare paired pre-DES and post-DES responses.
| Qualitative data collection and analysis
Following presentations of the hypothetical observational and randomized studies, the small groups discussed: (1) which of the 3 disclosure/consent models they found acceptable, (2) which they preferred for each study design, and (3) whether their opinions would be different in the context of a LHS. In addition, small group breakouts also discussed preferences among the disclosure/consent models for a study (not included in the quantitative survey) comparing minimally invasive surgery to epidural steroid injections for lower spinal stenosis.
All small group discussions were audio-recorded and transcribed.
De-identified transcripts were checked for accuracy and uploaded to NVivo10. Transcripts were independently coded by 2 study team members following a codebook developed for a previous study 12 and then reviewed by a third analyst to confirm and promote consistency of interpretation. Transcripts were coded for participants' attitudes towards the disclosure/consent models (eg, positive, negative, ambivalent), for reasons supporting their attitudes, and for explanations for changes in opinions. Coded texts were categorized into overarching themes. 
General Approval
• Patients are provided information through published institutional policies, newsletters, posters, and information sheets that their clinicians and care settings routinely conduct certain types of lower risk research that the institution thinks will not adversely impact patients' care, in order to ultimately learn which care is most effective. • Doctors will not routinely explain the study to patients during patients' appointments • There is no study-specific opportunity to opt-out of participation.
2 Opt-Out • Doctors will give patients a brief description of the study right before they are given their first blood pressure medicine • Patients are told that they will be part of the research study unless they say that they do not want to be part of it.
3 Opt-In • Doctors will give patients written and oral information about the objectives, risks, burdens, benefits, and alternatives of the study before they are given their first blood pressure medicine.
• Patients are then asked if they are willing to participate and a patient is not enrolled in research without the patient's express, voluntary, and written agreement. Patients can only be part of the research study if they give their written permission.
3 | RESULTS
| Study participants
Fifty-eight stakeholders, distributed among 8 small groups, participated in the DES. Among these, 28% identified their primary role as patients or patient advocates, and 21% as researchers. The remaining represented a mix of clinicians, health system administrators, research oversight experts, payers, and research funders (Exhibit 4). The group was evenly split between men and women, and the vast majority of participants (93%) were between the ages of 40 and 69.
| Quantitative results
Fifty-five of 58 participants completed both the pre-DES and post-DES surveys. For the observational hypertension study, 34% of respondents liked General Approval before deliberation, compared with 65% and 56% that liked Opt-Out and Opt-In, respectively (Exhibit 5). Following deliberation, 67% liked General Approval for this study design, 45% liked Opt-Out, and 36% liked Opt-In (P < .01 for all pre-post comparisons).
For the randomized hypertension study, respondents' views did not change significantly between the pre-DES and post-DES surveys.
Both before and after deliberation, fewer than 15% liked General
Approval, approximately half liked Opt-Out, and 80% liked Opt-In.
| Qualitative results
Discussions about the hypertension study differed somewhat from those about the spinal stenosis study. Each is described later.
| Case study 1: research to compare medications for hypertension
The majority of stakeholders preferred General Approval for the observational hypertension study. The most common explanation provided was that, assuming proper data security, this study involved no risk to patients. In explaining this choice, some noted that observational studies are regularly conducted without individual consent. An additional explanation put forward by several stakeholders was that General Approval would improve data quality, as it would include more patients than the other models. A few also suggested that there is a moral obligation to participate in this research. would like to know more information about that." A few participants noted that, even if most people would find General Approval acceptable, some individuals would be unhappy to learn that information about them was used without their permission. Participants favoring Opt-Out also raised concerns about the quality and accessibility of information provided via General Approval. A few described General
Approval as "meaningless" as there is no way to ensure that patients access or understand the information provided. These participants also raised equity concerns, as some patient subpopulations may be more likely to access and understand the information than others.
Five participants stated that Opt-In should be required for the observational study, but provided different explanations. Three favored Opt-In as a means to ensure information was delivered appropriately and to foster transparency and trust. One emphasized the value of shared decision-making in all interactions. Another argued that it is an "ethical violation" to disclose patient information (even if de-identified) without express, written consent.
In considering the appropriate model for the randomized hypertension study, there was little support for General Approval.
Participants were split fairly evenly between those who preferred Opt-Out versus preferring Opt-In.
Participants who favored Opt-Out justified this streamlined option because of the risk equivalence of the 2 medications, and physician equipoise regarding effectiveness. They felt that randomization required some form of individual disclosure, but thought a brief process with opportunity to refuse would suffice. As one described:
"For the randomized trial in this case, if these treatments are truly felt to be-we have no idea which one is better-I'd be comfortable with [Opt-
Out] just because the randomization process, I don't think, poses any other risk than the patients have going to a physician and being subject to their idiosyncratic decision making."
Another participant suggested that Opt-Out is a more honest approach, because, as (s)he described, "…I do not think that physicians
are very good at always describing their uncertainty to patients. I think that introducing these types of trials as an opt-out design really makes it clear for the patients that the provider thinks [they are] appropriate for this trial…"
A few participants who favored Opt-Out in this scenario referenced potential benefits for recruitment and implications for data quality. A common theme in several group discussions was that the question of whether someone has to opt-in or opt-out for a particular study is less important than the opportunity to make a decision. As stated by
participant: "…and I think the opt-in and opt-out is a distraction…The issue is informed consent is needed. Whether you opt-in or out is irrelevant."
Several people suggested that there should be no difference in the amount of information provided for Opt-Out versus Opt-In, and that patients should always have sufficient information about the risks and benefits, and adequate time to make a reasoned decision about participation. In addition, many participants expressed displeasure with the current approach to informed consent and supported more patient-centered approaches that value understanding over legal protection.
For the hypertension studies, participants were asked to reflect on whether the context of a LHS changed their views about disclosure and consent. The largest change was that half of participants who initially favored Opt-Out for the observational study indicated that they would The shift to viewing General Approval as acceptable was contingent on a LHS that clearly meets the description provided with regard to engagement, transparency, and accountability (Exhibit 3).
Several participants indicated that they would be more comfortable with General Approval if patients were given an opportunity to optout of all research when they enter the system. Some feared that, without this option, patients who were unable to choose a different health system due to financial or other reasons would be forced to participate in research.
There were minimal changes in opinion with regard to the randomized study, although a few participants did indicate that they would find General Approval acceptable in the context of a LHS. Many participants indicated that, although their preferred model would not change, they would feel much more comfortable with Opt-Out in a true LHS environment.
Regardless of opinions towards the models, the group as a whole responded very favorably to the concept of a LHS. They saw great value from ongoing patient engagement in the research process to improve study design and communication surrounding research. This favorability did not necessarily translate into support for the concept of an "ethics board." There was confusion regarding how such a group would be differentiated from the IRB, and some emphasized that it is more important to change the culture of the health system as a whole rather than to add a new component to the infrastructure.
| Case study 2: research to compare alternative treatments for spinal stenosis
Opinions about the best model for the observational spinal stenosis study were similar to those expressed for the hypertension study, with most preferring General Approval. Several stakeholders noted, however, the likelihood of needing more, and possibly more sensitive, information from patients to adequately address this research question. These stakeholders suggested that even the observational design would therefore require patient contact and, consequently, some kind of individual disclosure/consent.
The vast majority favored Opt-In for the randomized spinal stenosis study, including most who had favored Opt-Out for the randomized hypertension study. In explaining the difference, participants pointed to the higher level of risk associated with this study, the difference in level and type of risk between the 2 study arms, and the risk that patients would be randomized to a study arm that is inconsistent with their personal preferences. Participants in 1 group also discussed the distinction between consent to randomization and consent to treatment. They suggested that the consent to treatment would be required for both treatment options, and that this would provide an additional layer of patient protection and respect for autonomy. In other words, patients would have a second opportunity to decide about how their treatment would proceed, as they would be asked for their consent to be randomized and for their consent to the particular treatment to which they would be assigned.
| DISCUSSION
The primary aim of this study was to provide empirical information from a multi-stakeholder group regarding the perceived acceptability of 3 models of consent and disclosure for CER/PCOR studies. We sought to explore multi-stakeholder views for observational and randomized CER designs, within the context of a more straightforward (hypertension) and a more complicated (spinal stenosis) CER topic, and for CER conducted in the context of a learning health care system with commitments to engagement, transparency, and accountability.
In considering appropriate models of disclosure/consent for prospective observational CER for hypertensives, nearly 70% of stakeholders liked General Approval following deliberation. In this model, research studies would be described on websites and in patient newsletters, but study information would not be actively provided to individual patients and there would be no opportunity to opt out.
Support was nearly twice as high for General Approval for an observational CER study for hypertensives after deliberation as it was before, suggesting the DES method may have influenced multi-stakeholder attitudes toward streamlined consent approaches for CER. Notably, the majority of stakeholders also preferred General Approval for observational research for spinal stenosis.
In justifying their preference for General Approval, participants described both the minimal risk to the patient, and the benefit of more robust research findings. Several also described the observational study design as essentially mimicking current policy regarding record review research, already allowable without either disclosure or consent.
Our study found stronger support for General Approval in prospective observational studies than did prior surveys with patients or the general public. [12] [13] [14] For example, while over two-thirds of this multi-stakeholder group supported General Approval for an observational hypertension study following deliberation, only half of participants in an earlier patient-only DES did so. 12 One possible explanation for this difference is that stakeholders may be more aware than approaches for the generation of evidence to improve care delivery. 23 Our stakeholders were less supportive of streamlined approaches for randomized designs. By contrast, our earlier DES study of disclosure/consent preferences among patients found no difference in support for streamlined approaches for randomized studies as compared with observational designs. 12 These findings are consistent with those of Kraft et al, who found that, while patients generally had similar consent preferences for both observational and randomized studies, IRB professionals distinguished between different study designs when expressing preferences regarding approaches for disclosure/consent. 16 One explanation for this difference, suggested by prior qualitative work, is that IRB professionals may view observational research as less risky than randomized trials. 24 Qualitative comments from our participants support this hypothesis. Our qualitative data also suggest greater sophistication concerning research methodologies among diverse stakeholders than among patients or the general public, as well as potentially greater appreciation of other ways that randomization affects decisions about the course of treatment and patient valuesdistinctions which may have influenced their preferences regarding disclosure/consent approaches. For example, our stakeholders were able to identify other possible differences, such as differences in cost, that may influence patients' preferences for 1 treatment over another.
They also noted that Opt-In is particularly important when treatment options involved are different in kind or degree of risk or other characteristics that may be important to an individual patient or clinician.
In contrast to earlier studies in this area, we explicitly grounded our discussion of disclosure/consent models within the context of a LHS. Notably, the LHS context did not substantially affect our participants' attitudes towards disclosure/consent models for randomized CER studies. Nevertheless, some participants indicated that the parameters outlined by the hypothetical LHS might make them more comfortable with a streamlined approach to disclosure/consent for observational studies. To the extent that the LHS delivers on the promise of greater engagement, transparency, and accountability, stakeholders may be more open to alternative and streamlined approaches to disclosure/consent and also possibly research oversight.
Our findings provide insights into how diverse stakeholders think about disclosure and consent for CER, including the features of research that are important to them. However, they should be interpreted in light of several limitations. First, these results are based on a single multi-stakeholder DES; we do not know whether similar findings would be replicated with different or larger stakeholders groups. Second, this study design did not allow us to detect differences in opinion by stakeholder subgroup nor, in most cases, to know the stakeholder identity of a participant quoted on a small group transcript.
Third, racial and ethnic minorities were underrepresented among stakeholders attending the DES. While the research team sought to recruit a diverse group of individual stakeholders, our efforts were limited by our networks of existing contacts, and the degree of flexibility of stakeholders' work schedules to attend a full-day meeting in Baltimore. Consequently, some viewpoints may have been overlooked. Finally, we situated our discussion in the context of a hypothetical LHS. While this context may be instructive for health care systems looking to improve research and care integration, some stakeholders had difficulty envisioning health care settings beyond the current US health care and research paradigm. 
